ClaripulseClaripulse
MAUDE LookupResourcesBlog
LoginGet Early Access
ClaripulseClaripulse

Product

MAUDE LookupDashboard

Guides

FDA MAUDE DatabasePost-Market SurveillanceSignal Detection

Learn

BlogResourcesWhy Claripulse?

Legal

Privacy PolicyTerms of Service

This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified — do not attempt re-identification. © 2026 Claripulse.

Back to Coronary Intervention
MAUDE LookupCoronary InterventionEndeavor sprint

Endeavor sprint Adverse Events: FDA MAUDE Data

MEDTRONIC, INC. · Coronary Drug-Eluting Stent · First cleared Feb 2008

Total Reports

147

Reports (30d)

0

Active Signals

1

Open Recalls

0

Monthly Report Volume
Event Type Breakdown

Detection

Active safety signals

Disproportionate reportingmedium

Evidence

Related research

Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.

Valgimigli M, et al. · 2013

Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.

Song PS, et al. · 2015

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, et al. · 2013

Long-term outcome of sirolimus-eluting and zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a Danish organization for randomized trials on clinical outcome III substudy).

Olesen KK, et al. · 2014

Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.

Ariotti S, et al. · 2016

Citations indexed from PubMed.

Keep exploring

Related devices in Coronary

Perclose ProGlide

ABBOTT VASCULAR INC. · 24,504 reports

→

Perclose ProStyle

ABBOTT VASCULAR INC. · 19,336 reports

→

PERCLOSE

ABBOTT VASCULAR INC. · 9,890 reports

→

Angio-Seal

TERUMO MEDICAL CORPORATION · 6,417 reports

→

SYNERGY

BOSTON SCIENTIFIC CORPORATION · 5,991 reports

→

Resolute Onyx

MEDTRONIC, INC. · 4,467 reports

→

Want automated safety signal detection?

Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 1 active signal detected right now.

Get Early Access

Understanding this data

What FDA MAUDE data does and does not tell you

How these reports are filed, why raw counts mislead, and the limits to know before drawing conclusions.

→

How a safety signal is detected

What the "Active Signals" count above means and the methods that separate a real signal from noise.

→
Disclaimer: This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified. Do not attempt re-identification. Report counts may differ from the FDA's MAUDE search due to processing cadence and deduplication. Data is updated weekly.